| Unit Size | Cost | Quantity | Stock |
|---|
Amantadine exhibits neuroprotective and antiviral activity. Amantadine directly inhibits the viral M2 proton channel. This compound is also used to treat Parkinson’s disease; it inhibits monoamine oxidase A (MAO-A), α7 nicotinic acetylcholine receptors (nAChRs), norepinephrine transporters (NET), and NMDA receptors (through acceleration of channel closure).
| Cas No. | 665-66-7 |
|---|---|
| Purity | ≥98% |
| Formula | C10H17N • HCl |
| Formula Wt. | 187.71 |
| Chemical Name | Tricyclo[3.3.1.13,7]decan-1-amine hydrochloride |
| IUPAC Name | adamantan-1-amine;hydrochloride |
| Synonym | Amazolon, Mantadan, Mantadine, Symmetrel, Vitrofral |
| Melting Point | > 360°C (dec.) |
| Solubility | Soluble in water (400 mg/mL) or alcohol (196 mg/mL). Practically insoluble in ether. |
| Appearance | A white or almost white crystalline powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Sommerauer C, Rebernik P, Reither H, et al. The noradrenaline transporter as site of action for the anti-Parkinson drug amantadine. Neuropharmacology. 2012 Mar;62(4):1708-16. PMID: 22155208.
Jing X, Ma C, Ohigashi Y, et al. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10967-72. PMID: 18669647.
Blanpied TA, Clarke RJ, Johnson JW. Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. J Neurosci. 2005 Mar 30;25(13):3312-22. PMID: 15800186.
Pearce J. Mechanism of action of amantadine. Br Med J. 1971 Aug 26;3(5773):529. PMID: 4327681.
